Abstract：
Data on tumor immune-milieu after chemo-radiation (CT-RT) are scarce. Noninvasive tools are needed to improve the treatment of non-small cell lung cancer (NSCLC), especially in the locally advanced (LA) setting.
We collected a series of superior-sulcus (SS)- patients with NSCLC referred to our Institute (2015-2019), eligible for a preoperative CT-RT. We characterized tumor-infiltrating immune cells (TIICs), determined PD-L1-TPS and the residual viable tumor cells (RVTC). Radiological and metabolic responses were reviewed. We calculated pre-surgery neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).
Eight patients were included. Radiological responses were 6 disease stabilities (SD) and 2 partial responses (PR). Metabolic responses were 4 SD and 4 PR. CD68+-TIICs were correlated with metabolic response and lower RVTC. CD68+-TIICs were associated with higher PLR. Higher PLR values seemed linked with lower RVTC.
These preliminary results could be useful for consolidation treatment selection for patients with LA-NSCLC without evaluable baseline PD-L1 and higher PLR values.
We collected a series of superior-sulcus (SS)- patients with NSCLC referred to our Institute (2015-2019), eligible for a preoperative CT-RT. We characterized tumor-infiltrating immune cells (TIICs), determined PD-L1-TPS and the residual viable tumor cells (RVTC). Radiological and metabolic responses were reviewed. We calculated pre-surgery neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).
Eight patients were included. Radiological responses were 6 disease stabilities (SD) and 2 partial responses (PR). Metabolic responses were 4 SD and 4 PR. CD68+-TIICs were correlated with metabolic response and lower RVTC. CD68+-TIICs were associated with higher PLR. Higher PLR values seemed linked with lower RVTC.
These preliminary results could be useful for consolidation treatment selection for patients with LA-NSCLC without evaluable baseline PD-L1 and higher PLR values.
摘要：
化疗（CT-RT）后肿瘤免疫环境的数据很少。需要非侵入性工具来改善非小细胞肺癌（NSCLC）的治疗，特别是在本地高级（LA）设置。
我们收集了一系列上沟（SS）-NSCLC患者转诊到我们研究所（2015-2019），符合术前CT-RT的条件。我们表征了肿瘤浸润性免疫细胞（TIIC），确定PD-L1-TPS和残留的活肿瘤细胞(RVTC)。对放射学和代谢反应进行了综述。我们计算术前中性粒细胞与淋巴细胞比率（NLR）和血小板与淋巴细胞比率（PLR）。
纳入8名患者。放射学反应为6种疾病稳定性（SD）和2种部分反应（PR）。代谢响应为4SD和4PR。CD68+-TIIC与代谢反应和较低的RVTC相关。CD68+-TIIC与较高的PLR相关。较高的PLR值似乎与较低的RVTC有关。
这些初步结果对于没有可评估的基线PD-L1和更高的PLR值的LA-NSCLC患者的巩固治疗选择可能是有用的。
我们收集了一系列上沟（SS）-NSCLC患者转诊到我们研究所（2015-2019），符合术前CT-RT的条件。我们表征了肿瘤浸润性免疫细胞（TIIC），确定PD-L1-TPS和残留的活肿瘤细胞(RVTC)。对放射学和代谢反应进行了综述。我们计算术前中性粒细胞与淋巴细胞比率（NLR）和血小板与淋巴细胞比率（PLR）。
纳入8名患者。放射学反应为6种疾病稳定性（SD）和2种部分反应（PR）。代谢响应为4SD和4PR。CD68+-TIIC与代谢反应和较低的RVTC相关。CD68+-TIIC与较高的PLR相关。较高的PLR值似乎与较低的RVTC有关。
这些初步结果对于没有可评估的基线PD-L1和更高的PLR值的LA-NSCLC患者的巩固治疗选择可能是有用的。
